Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338786 | 0.75 | KDM4E (0.47) | GSK3AGSK3BDYRK1ACLK4KDM4E | |
| SCHEMBL1911502 | 0.73 | HSP90AB1 (0.38) | KDM4EALDH1A1GAALMNAMEN1 | |
| SCHEMBL6115978 | 0.73 | CSNK1A1 (0.46) | DYRK1ACLK4KDM4EMAPTHPGD | |
| SCHEMBL3256963 | 0.72 | GSK3A (0.48) | GSK3AGSK3BDYRK1ACLK4KDM4E | |
| SCHEMBL339246 | 0.71 | KDM4E (0.49) | GSK3AGSK3BDYRK1ACLK4KDM4E | |
| SCHEMBL23630302 | 0.71 | GSK3A (0.50) | GSK3AGSK3BDYRK1ACLK4KDM4E | |
| SCHEMBL1388588 | 0.70 | DHFR (0.59) | KDM4EMAPTADORA2AADORA1LMNA | |
| SCHEMBL338868 | 0.70 | KDM4E (0.40) | GSK3AGSK3BDYRK1ACLK4KDM4E | |
| SCHEMBL3369385 | 0.70 | ADORA1 (0.78) | GSK3AGSK3BDYRK1ACLK4KDM4E | |
| SCHEMBL28329968 | 0.69 | KDM4E (0.51) | GSK3AGSK3BDYRK1ACLK4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-2004643-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | GSK3A 2382/4885GSK3B 2067/4885DYRK1A 4778/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | GSK3A 2382/4885GSK3B 2067/4885DYRK1A 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.